Biotech
Seaport Therapeutics
Seaport Therapeutics raises $225M Series C at $1.2B valuation
Boston, MASeptember 12, 20241 min read
Total Raised
$225M
Valuation
$1.2B
Latest Round
Series C
Employees
100+
Seaport Therapeutics: Series C Funding Round
Seaport Therapeutics has successfully raised $225M in Series C funding, reaching a valuation of $1.2B.
Company Overview
Neuropsychiatric disease treatments
Funding Details
The Series C round was led by Fidelity, with participation from T. Rowe Price.
Company Information
- Headquarters: Boston, MA
- Founded: 2020
- Employees: 100+
- Category: Biotech
Investment
Seaport Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series C
- T. Rowe Price: Verified investor in Series C
Company Info
Headquarters
Boston, MA
Founded
2020
Team Size
100+
Last Round
$225M(Sep 2024)
Investors (2)
F
FidelityLeadLead Investor
Verified investor in Series C
T
T. Rowe PriceInvestor
Verified investor in Series C
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free